Novartis Oncology
|
Novartis AG provides healthcare solutions that address the evolving needs of patients and societies.
More from Zoominfo » |
Genta announces Phase 3 trial results of Genasense
Genta Incorporated today announced preliminary results from AGENDA, the Company’s Phase 3 trial of Genasense® (oblimersen sodium) Injection in patients with advanced melanoma. AGENDA is a randomized, double-blind, placebo-controlled trial of dacarbazine (DTIC) administered with or without Genasense® in patients who have not previously received chemotherapy.
From News-Medical-Net - 5 days ago
More news from Yahoo! News
|
|
|